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ABSTRACT 
BACKGROUND: Patients with chronic kidney disease (CKD) undergoing maintenance 
hemodialysis therapy suffer from a variety of co-morbid conditions that greatly decrease physical 
function and increase cardiovascular disease (CVD) mortality. Oxidative stress has been 
implicated in increasing CVD risk and declining muscle function in hemodialysis patients, but 
little is known about the efficacy of antioxidant treatment in this population. A recent one year 
intervention in dialysis patients found that consumption of pomegranate juice, a rich source of 
polyphenol antioxidants, significantly lowered serum markers of inflammation and oxidative 
stress, reduced carotid atherosclerosis, and lowered the prevalence of hospitalizations due to 
infection. Despite these potential benefits, pomegranate juice is normally contraindicated in 
hemodialysis patients because its high potassium content may contribute to 
hyperkalemia-induced cardiac dysfunction. As a result, the efficacy of alternative antioxidant 
therapies needs to be investigated.   
PURPOSE: The purpose of this study was to evaluate the effect of 6-month oral 
supplementation with a pomegranate extract containing a high concentration of antioxidant 
polyphenols, but low potassium content, on cardiovascular risk, physical function, oxidative 
stress and inflammation in hemodialysis patients.  
 iii 
METHODS: Thirty-three hemodialysis patients were recruited (20 men, 13 women; 54.3±2.1 
years). Subjects were randomized to pomegranate (POM, n=16) or placebo (CON, n=17) group. 
At baseline and 6 months following the start of the intervention, cardiovascular risk was assessed 
by measuring arterial structure and function using a combination of vascular ultrasound and 
arterial tonometry, as well as circulating markers of oxidative stress and inflammation. In 
addition, a variety of tests were used to assess muscle strength and physical function.  
RESULTS: Systolic and diastolic blood pressure (BP) were reduced by 24.2±13.7 mmHg and 
10.9±5.3 mmHg, respectively, in POM (p<0.05), but did not change in CON. However, the BP 
differences in the POM group were no longer significant after controlling for baseline BP levels.  
Paraoxonase-1 activity, a measure of antioxidant capacity, increased by 26.6% (p<0.05) in POM, 
compared to no significant change in CON. However, pomegranate supplementation had no 
effect on other markers of CVD risk (e.g., β stiffness index, augmentation index, pulse wave 
velocity, or carotid intima-media thickness (CIMT)), serum markers of inflammation and 
oxidative stress, or measures of physical function and muscle strength.   
CONCLUSION: This data suggests that while pomegranate extract supplementation may 
reduce blood pressure in hemodialysis patients, it does not improve other markers of 
cardiovascular risk, physical function or muscle strength.   
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CHAPTER 1 
INTRODUCTION 
 
The prevalence of chronic kidney disease (CKD) in the United States has increased 
dramatically in the past decade. In particular, the prevalence of advanced kidney disease, defined 
as end-stage renal disease or kidney failure (CKD stage 5) treated with dialysis or transplantation, 
increased by nearly 20% in the US in the decade following 2000
1
. Compared to age- and 
gender-matched healthy controls , patients with end-stage renal disease treated with hemodialysis 
have a 10- to 30-fold increased risk of cardiovascular disease (CVD) mortality, which constitutes 
58% of all-cause deaths in this population. Most patients with impaired renal function die of 
CVD rather than progress to renal failure, and the risk increases as renal function worsens
2-4
. 
Patients treated with hemodialysis also have greatly reduced levels of physical functioning. 
Muscle catabolism and wasting are especially common and lead to reduced muscle strength. 
Physical inactivity exacerbates these functional declines, and also promotes CVD. This cycle of 
disease and disability greatly reduces quality of life and increases mortality rates in CKD 
patients
5
.   
2 
 
Excessive oxidative stress is believed to underlie many of the cardiovascular complications 
in this population, including increases in carotid intima-media thickness (CIMT), arterial 
stiffness, atherosclerosis, vascular calcification, and left ventricular hypertrophy (LVH)
6-8
. In 
addition, studies have shown that increased oxidative stress contributes to inflammation which 
promotes skeletal muscle protein catabolism and atrophy in patients with kidney failure
4, 9
. This 
suggests that antioxidant therapy could be efficacious in CKD patients, potentially to attenuate 
declines in both cardiovascular disease risk and muscle function.  
In most populations, studies examining the effects of antioxidants (e.g., vitamin C, E, and 
β-carotene) on CVD risk have been disappointing10. In contrast, several studies in hemodialysis 
patients have shown that antioxidants may be effective in reducing CVD events
11, 12
. This 
indicates that antioxidant therapy may be more efficacious in hemodialysis patients than in other 
populations, possibly due to their excessive oxidative stress or other unique characteristics of the 
disease. However, few studies have examined this question.  
Although the efficacy of antioxidant supplementation for primary or secondary prevention 
of muscle atrophy or dysfunction is limited, recent research indicates that novel antioxidants 
such as N-acetylcysteine
13
, as well as isolated polyphenolic compounds
14, 15
 which have higher 
antioxidant activity than standard supplements, can indeed improve muscle strength or reduce 
muscle catabolism. In particular, a recent study by Trombold et al.
14
 found that 9 days of 
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pomegranate extract supplementation improved the recovery of isometric strength after eccentric 
exercise in healthy males. However, no studies to date have assessed the effects of antioxidant 
supplementation, or pomegranate specifically, on muscle strength or function in CKD patients.  
Pomegranate fruit is enriched in polyphenols with high antioxidant capacities. Pomegranate 
juice was recently shown to improve CVD risk in patients with carotid artery stenosis by 
reducing CIMT in association with reductions in blood pressure and serum oxidative stress
16
, and 
also has anti-inflammatory effects
17, 18
. In addition, a recent study in hemodialysis patients  
found that consumption of a very modest amount of pomegranate juice (~100ml/day) 3 days per 
week for one year significantly reduced markers of inflammation and oxidative stress, carotid 
atherosclerosis, and hospitalizations due to infection
19
. However, the patients in this study were 
required to consume the pomegranate juice immediately prior to their dialysis sessions so that the 
high potassium load from the juice could be removed in the dialysate. A potentially efficacious 
alternative strategy is to supplement patients with a pomegranate extract containing abundant 
antioxidant polyphenols, but only trace amounts of potassium.    
The objective of this research was to determine if daily oral supplementation with a 
pomegranate extract can lower CVD risk and attenuate declines in physical function in 
hemodialysis patients. To examine this, we conducted a double-blind, placebo controlled 
clinical trial in which 33 patients receiving maintenance hemodialysis therapy were randomized 
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to the following groups for 6 months: 1) Control/placebo (CON; N=17), or 2) Daily 
supplementation with a 1,000mg capsule of a pomegranate extract (POM; N=16). We 
hypothesized that POM supplementation would: 1) reduce systemic markers of inflammation and 
oxidative stress; 2) reduce arterial stiffness and CIMT; and 3) attenuate declines in physical 
function and strength. Results from this study will help determine if pomegranate extract is an 
efficacious means of preventing the development and progression of CKD co-morbidities.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Chronic Kidney Disease: Consequences of a Growing Epidemic   
The prevalence of chronic kidney disease (CKD) in the United States has increased 
dramatically in the past decade. In particular, the incidence of advanced kidney disease, defined 
as kidney failure (glomerular filtration rate (GFR) < 15 ml/min/1.73 m
2
 body-surface area) 
treated with dialysis or transplantation, increased in incidence by 43% in the United States in the 
decade following 1991
20
. Advanced CKD is associated with a variety of metabolic disturbances 
that increase morbidity and mortality. In addition, oxidative stress/antioxidant imbalance, muscle 
wasting, and cardiovascular complications are especially common, and these co-morbidities 
greatly reduce physical function and quality of life in dialysis patients. As a result, new strategies 
aimed at improving the health and quality of life of dialysis patients are needed.   
 
2.2 Cardiovascular Disease – The Leading Cause of Death in CKD Patients   
CVD is the leading cause of death in CKD patients, and the risk increases as the severity of 
the CKD increases. Greater than 58% of premature deaths in dialysis patients have been 
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attributable to CVD (reviewed in
21
). This increased CVD mortality is due to a variety of 
inter-related factors, including excessive vascular calcification (VC)
22-24
. VC is part of a 
remodeling of the vascular wall in CVD that promotes arterial and aortic stiffness
25
, as well as 
other deleterious functional outcomes, including increases in arterial wall intima-media thickness, 
endothelial dysfunction, changes in atherosclerotic plaque stability, and a variety of clinical end 
points, such as LVH
25, 26
.   
Studies have demonstrated that arterial stiffness is associated with LVH and an independent 
predictor of all-cause and cardiovascular mortality in dialysis patients
27-30
. In patients with stage 
5 CKD, with the progression of anemia, a decrease in the blood viscosity, and the creation of 
arteriovenous (AV) shunt, the peripheral resistances are most frequently normal or lower. Thus, 
the principal pressure factors opposing LV ejection are arterial stiffness and early return of wave 
reflections
27, 31
 . In patients with CKD, arterial function alterations are associated with arterial 
remodeling including intima-media hypertrophy of arteries
26
, characterized by stiffening of the 
arteries. Arterial stiffness is a major determinant of left ventricular pressure overload and of 
abnormal coronary perfusion in this population
32
.  
Traditional pharmacological therapies used to treat or prevent CVD in patients with normal 
renal function (e.g., lipid lowering medications) are generally less effective in CKD patients, 
possibly due to the excessive CVD risk observed in this population which is not fully accounted 
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for by traditional CVD risk factors
33
. A part of the extra risk is also attributable to renal-specific 
risk factors, related to uremia, including inflammation, malnutrition, and oxidative stress
34
. 
Elevated plasma concentration of pro-inflammatory cytokines and of the acute-phase reactant 
c-reactive protein (CRP) are among the strongest risk predictors of subsequent cardiovascular 
morbidity and mortality in uremic patients
35-37
.     
 
2.3 Muscle Catabolism in Dialysis Patients   
CKD Patients treated with hemodialysis are characterized by a severely limited exercise 
capacity
38
, reduced skeletal muscle strength and loss of lean muscle mass
39
. Evidence suggests 
that muscle atrophy in dialysis patients is the result of an enhanced muscle proteolysis
40
, and it is 
associated with several metabolic abnormalities that stimulate protein degradation
41
. Metabolic 
acidosis, commonly occurring in dialysis patients, causes loss of muscle mass by activating 
irreversible oxidation of essential, branched-chain amino acids 
42
. This suggests that reduction in 
muscle wasting might be achieved with correction of acidosis or the resulting oxidative stress in 
dialysis patients
43
.  
Insulin resistance, another common complication in dialysis patients, could also accelerate 
muscle atrophy by activating the ubiquitin-proteasome system in muscle 
44
. The 
(ATP)-dependent ubiquitin-proteasome proteolytic pathway is considered to be the major 
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process to remove damaged proteins produced by genetic alterations or by oxidative stress. 
Evidence for this includes the presence of higher levels of the transcription of ubiquitin and 
subunits of the proteasome
44-46
. Two ubiquitin ligases, atrogin-1 (also known as MAFbx) and 
MuRF-1, are found specifically in muscle, and their expression increases dramatically in 
catabolic states, causing loss of muscle protein
47
. Additional evidence linking the 
ubiquitin-proteasome proteolytic pathway to protein degradation in catabolism is the finding that 
the increase in protein degradation in the muscle of rats with CKD can be blocked by inhibitors 
of the proteasome
45, 46
.  
A third mechanism causing loss of protein stores is that the dialysis procedure itself 
stimulates protein degradation in muscle 
48
. The most convincing evidence that suggests 
increased protein breakdown induced by hemodialysis was provided by Gutierrez et al.
49
. These 
investigators showed increased amino acid release from the leg during sham hemodialysis in 
normal subjects using a bioincompatible dialyzer, but not with biocompatible membranes.  
Furthermore, evidence indicates that levels of circulating inflammatory cytokines are elevated 
during kidney disease progression, and these cytokines, such as tumor necrosis factor-alpha 
(TNF-α) and interleukin-6 (IL-6), have been suggested to be responsible for muscle catabolism50, 
51
 via up-regulation of the ubiquitin-proteasome proteolytic pathway 
52
.  
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Finally, oxidative stress, an imbalance between free radical formation and antioxidant 
status, is the major contributor to increased levels of circulating inflammatory cytokines and 
associated with accelerated protein catabolism in dialysis patients by up-regulating elements of 
the ubiquitin conjugation pathway
53
. In summary, there are several oxidative balance 
abnormalities in skeletal muscle of CKD patients that can stimulate protein degradation and lead 
to loss of muscle mass. 
 
2.4 Chronic Inflammation and Oxidative Stress in CKD  
As increased oxidative stress and inflammation are both common features of CKD, it has 
been suggested that they may be mechanistically linked
54-56
. Excessive oxidative stress is 
believed to be involved in triggering the inflammatory process by elevating circulating levels of 
acute phase proteins such as CRP and pro-inflammatory cytokines (especially IL-6 and TNF-α)7, 
36, 57
, and is also a significant contributor to the accelerated pathology associated with CKD
58-60
.   
 Oxidative stress, resulting from the imbalance of reactive oxygen species (ROS) production 
and anti-oxidant defense mechanisms, is correlated with the level of renal dysfunction among 
patients with CKD
7, 61
. The increased oxidative stress in CKD patients is mainly attributed to the 
retention of oxidized solute due to the loss of filtration function of the kidney, and the increase in 
oxidative stress becomes more pronounced as renal function deteriorates
58, 62
. In addition, 
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blood-membrane interaction during hemodialysis triggers circulating neutrophils to produce high 
amounts of ROS, including superoxide anion, hydrogen peroxide, hydroxyl radical, and 
hypochlorous acid
63
. Therefore, hemodialysis treatment has been proposed to impose additional 
oxidative stress on patients with end-stage renal disease because of the imbalance between ROS 
production and antioxidant defense mechanisms.  
ROS, which are generated both physiologically and pathologically, cause damage to cellular 
constituents, including membrane lipids, proteins, and DNA. In recent studies, the plasma 
concentration of oxidative stress markers such as malondialdehyde (MDA), a byproduct of the 
peroxidation of polyunsaturated fatty acids, and oxidized low-density lipoprotein (ox-LDL) were 
noted to be significantly increased in dialysis patients and have also been used to predict 
mortality in uremic patients
64-66
. Studies also demonstrate significantly elevated serum 
concentrations of CRP and F2-isoprostane, a biomarker of lipid oxidation, in hemodialysis 
patients compared with patients with normal kidney function
67, 68
.   
Plasma levels of protein carbonyls and advanced oxidation products of proteins (AOPP), an 
index of oxidant-mediated protein damage, are significantly increased in uremic patients
69, 70
. In 
addition, AOPP levels were found closely related to advanced glycation end products (AGEs) 
and monocyte activation markers in dialysis patients
71
. Finally, AOPP was identified as a marker 
of oxidative stress and a potent trigger of the monocyte respiratory burst in this population.   
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In contrast to lipids and proteins, the reactions of DNA with various oxidants have not been 
well studied in hemodialysis patients. Phagocytes are activated after contact with 
bioincompatible dialyzer membranes, so, leukocytes of patients undergoing chronic 
hemodialysis may be useful for monitoring changes in the level of cellular DNA oxidation as 
they are not only the source, but also the target of endogenously produced ROS and free radicals. 
Among the many types of modifications induced by ROS, 8-hydroxy-2’-deoxyguanosine 
(8-OHdG) is one of the most abundant oxidative products of DNA
72, 73
, and is capable of 
reflecting extremely low levels of oxidative DNA damage and is therefore useful as a surrogate 
marker of oxidative stress in hemodialysis patients
74
. Hemodialysis patients exhibit increased 
oxidative DNA damage, compared to age- and sex-matched healthy individuals. Furthermore, 
endothelial function has been shown to be negatively correlated with 8-OHdG in hemodialysis 
patients
75
.  
 
2.5 Impairment in Antioxidant Defense System   
Several intracellular and extracellular antioxidant systems have evolved to detoxify specific 
free radicals and other oxidants. However, antioxidant mechanisms that serve as a safeguard 
against ROS seem to be impaired in hemodialysis patients, and deficiencies in different 
components, including reduced levels of enzymatic antioxidants (e.g., superoxide dismutase 
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(SOD), glutathione peroxidase (GSH-Px), and catalase (CAT))
76, 77
 and extracellular antioxidant 
defense elements (such as reduced glutathione (GSH))
78, 79
. Furthermore, decreased levels of 
hydrophilic and lipophilic antioxidant vitamins in uremia have also been observed
34, 80, 81
; if 
antioxidant defense is compromised, elevated ROS formation in the body will lead to increased 
damage. 
 
2.6 Effects of Single Hemodialysis Sessions   
Hemodialysis is a non-selective process clearing solute solely based on molecular weight, a 
sieving property of the membrane and protein bound capacity. Consequently, hemodialysis 
induces solute losses, including antioxidants. In addition, hemodialysis per se has been suggested 
to induce oxidative stress, with ROS being generated on the surface of dialysis membranes
82-84
. 
Indeed, it has been well documented that even a single session of hemodialysis significantly 
increases lipid peroxides and decreases antioxidants
85-88
.  
Contribution of the dialyzer membrane in the production of inflammation and ROS has 
been studied in acute hemodialysis conditions by comparing cellulosic (cuprophane) and 
synthetic (polysulfone) dialyzer membranes
63, 89
. Plasma levels of inflammatory cytokines (such 
as IL-6 and TNF-α) are elevated in dialysis patients, and their expression was exacerbated further 
even after a single dialysis treatment
90, 91
. Although there are controversial results in the literature 
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indicating that hemodialysis could improve lipid profiles in hemodialysis patients
92
, others have 
indicated an increase in lipid peroxidation during hemodialysis
89, 93
. The majority of ROS 
generated during a single dialysis session is hydrogen peroxide
91
 which causes subsequently lipid 
peroxidation, which enhances the susceptibility of LDL oxidation and is recognized as the major 
initiating event in the genesis of atherosclerosis. Besides the alterations in lipid levels, 
hemodialysis treatment also contributes to increased oxidative stress at the protein level
89, 94
.  
ROS can not only inactivate mitochondrial enzymes or damage lipid, protein and DNA, but 
also actively react with nitric oxide (NO), a principal endothelial-derived relaxing factor, to yield 
the powerful oxidant, peroxynitrite (ONOO
−
). The inactivation of NO by ROS creates NO 
deficiency and could play a role in the arterial stiffness.  
Interestingly, NO production during hemodialysis is increased rather than decreased
95-98
. 
Most studies indicate that NO increases early during dialysis, possibly due to shear stress or 
leukocyte activation by the dialysis membrane
82, 83, 95, 96, 99
; however, a significant drop in NO 
levels usually occurs at the end of dialysis
98, 100
, probably due to its elimination during the 
dialysis session, and returned to high levels between the sessions. The increased NO production 
is, however, attacked by superoxide and other ROS released as a result of bioincompatibility of 
the dialyzer membrane. This results in formation of ONOO
− 
which release hydroxyl radicals. 
The hydroxyl radicals in the presence of fatty acids released by the lipolytic effect of heparin 
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perpetuate the oxidative stress and cause the ONOO
−
 diverted toward lipid peroxidation. As a 
result, hemodialysis can be seen as a situation of continuous production of NO, with 
simultaneous inactivation by ROS, leading to endothelial dysfunction
101
. 
 Given the intimate causal interaction between oxidative stress and inflammation, 
interventions that aim to alleviate oxidative stress can potentially ameliorate inflammation. 
Several clinical studies have attempted to treat oxidative stress and inflammation in this 
population by a variety of antioxidant regimens. Many of these studies have employed vitamin E 
or C given either orally or parenterally
10, 79, 102
; however, these studies have produced conflicting 
results and lack of acute responses to single antioxidant intervention. These data may be partially 
explained by a vitamin C-related increase in catalytic iron and oxalate that favors prooxidant 
activity; different doses and route of antioxidant administration and different markers of 
oxidative stress may also help explain the results.  
 
2.7 Oxidative Stress, Antioxidants and CVD in CKD 
Elevated oxidative stress is a common feature in CKD patients that likely contributes to 
their excessive CVD risk
34, 103-105
. Increased oxidative stress results in vascular injury and a 
variety of functional CVD outcomes, including increases in arterial stiffness
106
, vascular 
dysfunction
107
, CIMT
108
, and vascular calcification
109
(Figure 1).  
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Superoxide anion, a primary ROS which is generated from a one-electron reduction of 
molecular oxygen, may inactivate nitric oxide (NO) and diminish its bioavailability, thus 
ultimately lead to endothelial dysfunction
110, 111
. Endothelial dysfunction is especially important 
in renal disease, given the nature of accelerated risk of CVD in this population.  
Because inflammation, oxidative stress and the pathogenesis of CVD are closely 
intertwined, and oxidation products may mediate inflammation in CKD patients, antioxidant 
supplementation is of particular interest
12, 81
. Due to the excessive oxidative stress in patients 
with advanced CKD, antioxidants may be particularly effective in this population. 
Despite a demonstrated lack of efficacy of vitamin E in most clinical trials, studies recently 
showed that oral vitamin E supplementation reduced the incidence of myocardial infarction
11
 and 
improved oxidative stress
79
 in CKD patients. Similarly, Tepel et al showed that twice daily 
supplementation with 600mg of the antioxidant N-Acetylcysteine (NAC) reduced cardiovascular 
endpoints by 40% in CKD patients
12
. Yet, few studies have linked the reduced oxidative stress to 
the functional cardiovascular outcomes in CKD patients.  
Most previous trials assessing the efficacy of antioxidants have used single compounds such 
as β-carotene, vitamin A, vitamin C, vitamin E, and selenium, each of which has rather limited 
substrate specificity. Also, antioxidants vary significantly in their capacity to scavenge free 
radicals, chelate transition metal ions, and/or inhibit oxygenase/oxidase activity. A more 
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efficacious approach may be to use combinations of antioxidants with diverse substrate 
specificities. 
 
2.8 Effects of Antioxidants on Muscular Performance 
Several lines of evidence link ROS to muscle atrophy via reductive-oxidative (redox) 
control of proteolysis. Importantly, a growing number of studies suggest that antioxidants can 
serve as therapeutic agents in delaying the rate of muscle atrophy. 
Abundant research demonstrated that oxidative stress contributes to muscle atrophy, and this 
phenomenon could be delayed by exogenous antioxidants.   
A recent cross-sectional study supports the hypothesis that oxidative stress is associated 
with the loss of muscle mass in older adults
112
. Findings from this study showed that higher 
plasma concentrations of antioxidants were associated with reduced risk of low grip, hip, and 
knee strength. Similarly, reduced muscle damage in claudicants was found with daily 
administration of vitamin E (200mg) and vitamin C (500 mg) for 4 weeks
113
. These findings 
suggest that antioxidants may play a role in preventing oxidative protein modification in muscle 
and preserving muscle function. The work of Appell et al. revealed that there was less oxidative 
stress in the vitamin E supplemented muscles than the control group in rats, and eight days of 
immobilization lead to a 35% atrophy, while with vitamin E the muscles atrophied only by 
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12%
114
. This difference can be attributed to the action of vitamin E as a scavenger for free 
radicals and, on the other hand, to an atrophy promoting effect of oxidative stress.   
Another study also showed that Trolox attenuates the mechanical ventilation-induced 
diaphragmatic contractility deficit. Mechanical ventilation is associated with a rapid onset of 
protein oxidation in
 
diaphragm fibers, and has been directly linked to activation of the ubiquitin–
proteasome
 
system of proteolysis. However, diaphragmatic proteolysis did not differ between 
controls and mechanical ventilation-Trolox animals. Moreover, proteasome activity in the 
diaphragm was elevated in the mechanical ventilation animals, while Trolox treatment attenuated 
this mechanical ventilation-induced rise in protease activity
115
. 
Hauer et al. 
13
 performed a randomized, placebo-controlled trial in the elderly with 13 
weeks of 200 mg N-Acetylcysteine (NAC) supplementation. NAC is a precursor for glutathione, 
an important antioxidant that protects cells against oxidative stress. NAC administration resulted 
in improvement in muscle strength and decrease in TNF-α level, and suggesting a potential 
anti-inflammatory role. In addition, a recent study showed that supplementation with 
ellagitannins from pomegranate extract significantly improved isometric strength 2-3 days 
following damaging eccentric elbow flexion exercise in recreationally active males
14, 15
. The 
recovery of strength during the 24- to 48-h period was more rapid, and strength was significantly 
higher in the subjects who consumed 500mL of pomegranate extract beverage, compared to the 
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placebo group. Together, these findings suggest that antioxidant supplementation, including 
pomegranate extract, may improve muscular performance. Furthermore, the effect of antioxidant 
supplementation on the muscular performance might be mediated through changes in the levels 
of inflammation and oxidative stress. 
 
2.9 Pomegranate – A Rich Source of Potent Antioxidants   
A specific source of antioxidants with therapeutic potential in dialysis patients is 
pomegranate fruit (Punica granatum L.), which contains a variety of polyphenols and other 
antioxidants, including punicalagin, anthocyanins, ellagic acid and gallic acid, that have 
particularly potent and diverse antioxidant capacities
116, 117
. The antioxidant capacity of 
pomegranate juice was shown to be three times higher than that of red wine and green tea, based 
on the evaluation of the free-radical scavenging and iron reducing capacity of the juices
116
.   
Pomegranate also has been reported to inhibit lipid peroxidation
118
, and pomegranate 
showed better protection than vitamin E and NAC against oxidative stress
119
. In addition, 
pomegranate may inhibit inflammation-stimulated c-Jun N-terminal kinases (JNK)- and 
extracellular signal-regulated kinase (ERK)- mitogen-activated protein kinase (MAPK) 
activation through the suppression of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NK-kB) activity
17
, increasing endothelial NO synthase expression
120, 121
, and reducing 
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atherosclerotic lesions
122
. But unlike most studies using single antioxidants, several small clinical 
trials indicate that pomegranate juice or extracts also help reduce CVD risk in humans. 
Recently, Aviram et al. showed that 1 year of pomegranate juice consumption by patients 
with severe internal carotid artery stenosis reduced CIMT by 30%, increased antioxidant 
capacity by 130%, and substantially inhibited LDL-lipid peroxidation
16
. In a follow-up study 
with subjects at moderate risk for CHD, 1 year of pomegranate juice consumption attenuated 
anterior wall CIMT progression, which was thicker at baseline than posterior wall CIMT, while 
pomegranate juice showed little or no effect on progression rates in the posterior wall CIMT
123
. 
Furthermore, in the subgroup of patients with the greatest risk of CVD, those in the pomegranate 
juice group had less CIMT progression versus control subjects. This finding suggests that 
pomegranate may be most efficacious in subjects with the greater oxidative stress and/or CVD 
risk. In addition, pomegranate juice and extract consumption in diabetics resulted in a significant 
improvement in markers of oxidative stress and atherogenesis without worsening their diabetic 
parameters
124, 125
. Another potential benefit of pomegranate is that it has been shown to increase 
endogenous antioxidant activity
16
, suggesting another potential mechanism for its 
cardioprotective effects.  
Evidence for the clinical benefits of pomegranate juice in the patients undergoing 
hemodialysis was recently reported by Shema-Didi et al.
19
 Hemodialysis patients who consumed 
20 
 
100 mL of pomegranate juice 3 times a week during dialysis sessions for 12 months had 
significant reductions in neutrophil, IL-6 and oxidized fibrinogen, while the placebo group had 
no change in levels of any of the markers. In addition, hospitalizations for cardiovascular causes 
were reduced by 40% in patients randomized to pomegranate juice, but did not change in the 
placebo group. However, pomegranate juice contains high concentrations of potassium, creating 
a potential for potassium overload in dialysis patients. No studies to date have examined the 
efficacy of pomegranate extract, which contains much lower concentrations of potassium than 
juice, on CVD risk or physical function in this population.  
Taken together, these data indicate that antioxidant intervention may be more efficacious in 
patients with excessive oxidative stress, such as patients undergoing hemodialysis treatment. In 
addition, pomegranate extracts may be more effective than single antioxidants in reducing CVD 
risk and attenuating muscle wasting in clinical populations.  
 
2.10 Safety and Drug Interactions 
Drug-dietary supplement interactions have been a concern in clinical research, and 
conflicting data regarding pomegranate's impact on hepatic P450 2C9 (CYP2C9) enzymes have 
been published. Case reports of patients experiencing potential drug toxicities while drinking 
pomegranate juice have been reported. One patient on warfarin had an increase prothrombin time 
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after introducing pomegranate juice into the diet
126
. Another subject experienced rhabdomyolysis 
after drinking pomegranate while on rosuvastatin and zetia combination therapy
127
. Both case 
reports, however, were confounded by preexisting conditions that may have explained observed 
results. A recent study investigated the effect of pomegranate juice and pomegranate extracts on 
inhibiting human CYP2C9 activity by using flurbiprofen as a probe compound to profile 
CYP2C9
128
. This study showed that pomegranate juice and pomegranate extracts inhibit 
CYP2C9 activity in vitro, but not in vivo. This finding indicates that subjects on CYP2C9-related 
medications can consume pomegranate juice or extract with little risk of drug-supplements 
interaction. 
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Figure Legends 
Figure 1 Mechanisms responsible for oxidative stress-induced increases in cardiovascular 
disease risk (modified from
105, 129
). Cardiovascular disease is one of the major complications of 
CKD patients undergoing dialysis. Other common co-morbidities in this population, such as 
hypertension, dyslipidemia, hyperglycemia, are centrally linked to increased oxidative stress and 
reactive oxygen species (ROS). Elevated oxidative stress and ROS can cause oxidation of 
tetrahydrobiopterin (BH4), a cofactor for the production of nitric oxide (NO) by endothelial 
nitric oxide synthases (eNOs), and consequently lead to uncoupling of eNOS. This reaction 
generates superoxide anion and causes decreased NO production and bioavailablilty. Superoxide 
anion can cause lipid peroxidation, accumulation of which contributes to endothelial 
dysfunction. Nitric oxide (NO) has been shown to be a potent vasodilator. Oxidative 
stress-induced reductions in NO production and bioavailability also promote endothelial 
dysfunction. This can impair microvascular vasodilatory capacity, elevate inflammatory levels, 
and increase arterial stiffness. Furthermore, these responses result in the development of 
cardiovascular complications, including atherogenesis, left ventricular hypertrophy and 
dysfunction, and myocardial ischemia. 
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Figure 1 Mechanisms responsible for oxidative stress-induced increases in cardiovascular 
disease risk (modified from
105, 129
).  
 
 
 
ROS, reactive oxygen species; BH4, tetrahydrobiopterin; NO, nitric oxide; eNOS, endothelial nitric oxide synthase. 
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CHAPTER 3 
RESEARCH DESIGN AND METHODS 
 
3.1 Study Overview  
Patients with renal failure receiving maintenance hemodialysis therapy (CKD stage 5) at 
local dialysis clinics were recruited and randomly assigned to one of two groups for 6 months: 1) 
Usual care/control (CON; N=14); or 2) Daily oral supplementation with a purified pomegranate 
extract (POM; N=13). Patients in the POM group ingested a 1,000mg capsule of a pomegranate 
extract every day for 6 months. Patients in the CON group ingested a placebo capsule using the 
same protocol. At baseline and 6 months following the start of the supplementation period, all 
patients had blood collected to measure markers related to inflammation, oxidative stress, and 
antioxidant capacity. The subjects also came in for clinical testing at each time point to measure 
factors related to cardiovascular disease (CVD) risk and physical function. A study timeline is 
shown in Figure 2. 
 
3.2 Subjects, Recruitment, Screening, and Selection  
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Thirty-three patients with CKD stage 5 (GFR < 15 ml/minute/1.73 m
2
) receiving 
hemodialysis therapy for more than 3 months were recruited on a rolling basis from the 
hemodialysis clinics in Champaign and Chicago, IL. Patients were recruited through 
advertisements that were placed in the clinics, as well as through brochures provided to subjects 
by the medical staff and research members. Those expressing an interest in the study signed a 
form indicating they would like to be contacted by a member of the research staff to acquire 
more information. During the screening, subjects were informed of the study purpose, the risks 
and benefits pertaining to their participation, the randomization process, the proposed testing, 
and the necessary time commitment. Patients were screened for eligibility by administering a 
medical history questionnaire (see exclusion criteria below), and an informed consent document 
was provided for each individual to sign upon their agreement to participate. A physician 
clearance for each subject was signed by their nephrologists. All protocols were approved by the 
Institutional Review Board of the University of Illinois.   
 
3.3 Inclusion/Exclusion Criteria 
Inclusion/exclusion criteria for volunteers include the following: 1) Subjects must be 
diagnosed with CKD stage 5, and had been receiving hemodialysis treatment 3 times per week 
for ≥ 3 months. This criteria was chosen based on research indicating oxidative stress increases 
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as renal function deteriorates
130
, and our working hypothesis is that pomegranate 
supplementation would be most efficacious in individuals with excessive oxidative stress. 2) 
Subjects must be ≥ 30 years of age. As previous studies have shown arterial stiffness increases 
significantly after 30 years of age in CKD patients (unpublished observations from our 
laboratory), and limiting the recruiting pool to those ≥ 30 years of age will reduce the number of 
recruited subjects with little or undetectable arterial stiffness. 3) Subjects must be willing to be 
randomized to the control or intervention groups. 4) Subjects must receive medical clearance 
from their primary care physician to participate. 5) Subjects must NOT be consuming any form 
of antioxidant supplementation.     
 
3.4 Group Assignment   
Following recruitment, screening, and baseline testing (see below), 33 eligible subjects were 
randomized to the CON or POM groups as described below. Both the subjects and study 
personnel involved in data collection were blinded to the group assignment. We used a simple 
randomization procedure as follows: the eligible subjects were randomly sorted into pairs. In 
each pair, a random permutation of the subjects is used to assign them to the two groups (CON 
or POM). Under this randomization procedure, each subject has equal probability of being 
assigned to each group. 
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3.5 Intervention Protocol   
Patients in the POM group ingested a 1,000mg capsule of a purified pomegranate 
polyphenol extract (POMx™, POM Wonderful, Inc. Los Angeles, CA; 
http://www.pompills.com/pills/product_pills.aspx) 7 days a week for 6 months. POMx pills are a 
concentrated blend of polyphenols extracted from whole pomegranates that have been safety 
tested by the Food and Drug Administration. The no-observed-adverse-effect level (NOAEL) of 
POMx was considered to be 1500 mg/kg of body weight (unpublished data, POM Wonderful 
LLC., 2006), which is approximately 100~125-fold more than what was being provided in this 
study. Research also showed that 1,000mg (610~755mg of gallic acid equivalents) of 
pomegranate extract is sufficient to provide antioxidant effects through a reduction in 
thiobarbituric acid reactive substances (TBARS), a byproduct of lipid peroxidation, in 
overweight subjects
131
.  
POMx is derived from pomegranates grown in California (Paramount Farms). POMx is 
prepared from inner and outer pomegranate peels, seeds and juice, pressed to produce a powder 
with a high concentration of polyphenols. The pomegranate extract is 98% (980 mg) of the pill’s 
active ingredient. The extract is composed of 5.7% ellagic acid, 25.6% punicalin/punicalagin, 
and 68.4% other polyphenols. The remaining 2% of the drug is magnesium stearate. The 
28 
 
matching placebo pills contain 0mg of gallic acid equivalents, and the ingredients include 
cellulose, caramel, beet root, magnesium stearate, and silicon (source: PomWonderful, 
unpublished data). The study drugs were stored at the Agricultural Engineering Sciences 
Building. Dry storage is required and shelf life is 18 months at or below 25˚C. 
 We chose to use the POMx pills instead of pomegranate juice because the juice contains 
significant amounts of potassium (430mg per 8 ounces or 12% of the recommended Daily Value 
for healthy adults), which is restricted in CKD patients, while the POMx pills have marginal 
levels (<0.998 mg per 1,000mg pill) of this mineral. Hyperkalemia, the condition of 
overabundance of potassium in the extracellular compartment, is common in patients with 
end-stage renal disease. Excess intake of potassium through dietary indiscretion and oral 
supplementation are the most common causes of hyperkalemia in dialysis patients. The effect of 
hyperkalemia on cardiac conductivity is its most feared clinical consequence, symptoms 
including slow pulse, irregular heartbeat, heart failure, and even sudden death. Severe 
hyperkalemia may also profoundly affect skeletal muscle, manifesting as motor weakness and 
parasthesia.  
Individuals in the CON group ingested a non-caloric placebo capsule using the same 
protocol. Patients in both groups received a pill bottle containing a month’s supply of capsules 
(POM or placebo) prior to the beginning of each month. They were asked to bring their pill 
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bottles to the dialysis clinics on a monthly basis so the number of remaining pills can be counted 
for compliance purposes. If a participant was non-compliant, defined as completing less than 
75% of the available supplements (and does not respond to repeated attempts to increase 
consumption), their data was not included in the analysis.  
 
3.6 Baseline Testing and Measurements   
3.6.1 Anthropometric Measures  
Barefoot standing height was measured to the nearest 0.1 cm with a stadiometer and body 
weight was measured on a balance scale with shoes and superfluous outer garments (e.g., 
jackets) removed. Waist circumference was measured as the minimum circumference between 
the top of the iliac crest and the distal end of the rib cage along the mid-axillary line. An 
additional measure of waist circumference was also taken at the umbilicus, and the average of 
the 2 waist circumference measurements was used in all analysis. Hip circumference was 
measured at the maximal hip circumference. All measurements for a given participant were taken 
in triplicate and averaged.   
 
3.6.2 Blood Chemistry 
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A small amount (20 – 30 ml) of blood was collected from each subject at baseline and 6 
months for analyses described below. Plasma and serum from these extra samples was collected 
by centrifugation, divided into 350ul aliquots, and stored at -80°C until analyzed.  
 
3.6.2.1 Oxidative Stress Biomarkers 
Advanced oxidation protein products (AOPP) are uremic toxins that are a marker of protein 
oxidative stress created through the reaction of plasma proteins with chlorinated oxidants, such 
as chloramines or hypochlorous acid. Concentration of AOPP in the plasma was determined 
using the semi-automated method as previously described
69
. Briefly, AOPP was measured by 
spectrophotometry on a microplate reader (GENios Pro, Tecan, Männedorf, Switzerland) and 
calibrated with chloramine-T (Sigma, St. Louis, MO) solutions that in the presence of potassium 
iodide absorb at 340 nm. In test wells, 200 µl of plasma diluted 1/5 in PBS was placed on a 
96-well microtiter plate, and 20 µl of acetic acid was added. In standard wells, 10 µl of 1.16 M 
potassium iodide (Sigma, St. Louis, MO) was added to 200 µl of chloramine-T solution (0–400 
µmol/liter) followed by 20 µl of acetic acid. The absorbance of the reaction mixture is 
immediately read at 340 nm on the microplate reader against a blank containing 200 µl of PBS, 
10 µl of potassium iodide, and 20 µl of acetic acid. AOPP concentrations were expressed as 
micromoles per liter of chloramine-T equivalents. 
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Oxidized low-density lipoprotein (ox-LDL), a marker of lipoprotein-associated oxidative 
stress
132
, was measured in triplicate using commercially available ELISA kits (Mercodia, 
Uppsala, Sweden). 
8-hydroxy-2’-deoxyguanosine (8-OHdG) is produced by oxidative damage of DNA by 
reactive oxygen and nitrogen species. It serves as a biomarker of DNA oxidation, and was 
measured in triplicate using commercially available ELISA kits (Trevigen, Gaithersburg, MD). 
 
3.6.2.2 Antioxidant Capacity 
The Oxygen Radical Absorbance Capacity (ORAC) assay was performed according to 
published methods by Prior et al.
133
 Fluorescein reacts with free radicals generated by 
2,2’-azobis(2-amidinopropane) dihydrochloride (AAPH) yielding a non-fluorescent product. 
Loss of fluorescence was measured over time in fluorescent plate reader, FLx800tbi (Bio-Tek, 
Winooski, VT), at 37 °C and sensitivity 60. Readings were made with excitation 485 nm and 
emission 528 nm. The area under the curve (AUC) was calculated using the following equation: 
 
AUC = 0.5 + f1 / f0 + fi / f0 + …+ 0.5 (fn / f0) 
Net AUC = AUCsample – AUCblank 
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Where AUC is area under the curve, f1 is fluorescence of first reading (2 min); f0 is fluorescence 
of reading time zero and fn are n fluorescence readings. Areas under the curve were compared to 
a standard antioxidant, Trolox (vitamin E analog). Results were expressed as μM Trolox 
equivalents. 
High-density lipoprotein (HDL) associated paraoxonase-1 (PON-1) is an antioxidant enzyme 
that protects lipoproteins from oxidation, and is considered a primary anti-atherosclerotic 
component of HDL
119, 134, 135
. Previous research has shown that pomegranate supplementation 
increases PON-1 activity in diabetic and healthy subjects
124, 136
. PON-1 activity, including 
arylesterase (monoesterase), paraoxonase (triesterase), and lactonase, was measured to assess 
serum antioxidant capacity as described
16, 137-139
.  
Lactonase, paraoxonase, and arylesterase activity was measured kinetically at 37°C using 
dihydrocoumarin, paraoxon, and phenyl acetate as a substrate, respectively. PON-1 activity was 
measured using a microplate reader (GENios Pro, Tecan, Männedorf, Switzerland), and the 
activity of lactonase, paraoxonase, and arylesterase was reported as units per milliliter, where 1 
U is defined as 1 mmol of dihydrocoumarin, paraoxon, and phenyl acetate hydrolyzed per 
minute, respectively.   
 
3.6.2.3 Markers of Inflammation   
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Serum CRP and IL-6 were measured in triplicate using commercially available ELISA kits 
(CRP:Alpco, Salem, NH ; IL-6: R&D Systems, Minneapolis, MN). To control for variation 
between runs, baseline and 6-month samples from each subject were analyzed simultaneously. 
Published intra-assay coefficients of variation were less than 5% for each assay.  
 
3.6.3 Cardiovascular Disease Risk Measures 
3.6.3.1 Blood Pressure 
Brachial systolic (SBP) and diastolic (DBP) blood pressure was obtained using standard 
methods following a 10-minute period of quiet supine rest in a dimly lit room. Brachial blood 
pressure was measured using an automatic digital blood pressure monitor (Omron IntelliSense 
HEM-907XL, IL). All the BP measurements were repeated and the average of the two values, 
1-minute apart, was recorded and used for analysis. If the values differed by ≥ 5mmHg, a third 
measurement was obtained and the two closest values were averaged. Mean arterial pressure was 
calculated by DBP + 1/3 (SBP-DBP). 
 
3.6.3.2 Carotid Artery Stiffness  
A combination of ultrasound imaging of the common carotid artery with simultaneous 
arterial tonometry of the carotid artery (for estimation of carotid blood pressure) allows for a 
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non-invasive determination of carotid arterial compliance. Carotid ultrasound images were 
obtained from the common carotid artery, 1-2 cm proximal to the carotid bifurcation using a 7-13 
MHz linear array transducer with a sampling rate of 1,000 Hz. B-Mode and M-mode images 
were obtained and displayed simultaneously and automated wall tracking software was used to 
detect changes in lumen size as described above. Electronic calipers were applied to the arterial 
wall using the B-mode image and wall tracking is conducted using the M-mode image in real 
time. Changes in lumen size between systole and diastole is recorded for 12 seconds and an 
ensemble average beat is constructed from which measurements of arterial compliance and 
stiffness was conducted. -stiffness index (β) was calculated with lumen size in systole and 
diastole. The calculation for  is shown below:  
             
 = In (Ps – Pd) / (Ds – Dd)  
 
Ps=systolic pressure, Pd=diastolic pressure, Ds = maximum vessel diameter, and Dd = minimum 
vessel diameter.   
Carotid blood pressure was estimated using simultaneous arterial tonometry on the 
contralateral carotid artery. A high fidelity pencil probe strain gauge transducer (Millar 
Instruments, Huston, Texas) was interfaced with acquisition software (SphygmoCor, AtCor 
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Medical, Sydney, Australia). The carotid waveform was calibrated against brachial artery 
pressure to derive carotid artery pressure using standard transfer functions (SphygmoCor, AtCor 
Medical, Sydney, Australia).  
 
3.6.3.3 Carotid Intima-Media Thickness (CIMT)  
CIMT were measured using a high-resolution ultrasound
 
system (Aloka Alpha 7, Japan) 
with a 7-13 MHz linear array transducer. The common carotid artery
 
was imaged at the proximal 
1-2 cm straight portion. The carotid bifurcation or bulb was used as a reference point to 
standardize the position of the CIMT measurements between baseline and final testing when 
possible. All images were analyzed in a 10mm window which is 10mm distal to the bulb using 
Carotid Analyzer (Medical Imaging Applications, LLC, Coralville, IA) software. The 
intima-media thickness was defined as the distance between the leading edge of the 
lumen-intima interface to the leading edge of the media-adventitia interface of the
 
far wall of the 
carotid artery. All measurements and analysis were made by the same trained investigator 
blinded to group assignment.  
 
3.6.3.4 Wave Reflection  
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Applanation tonometry was performed using a high-fidelity strain-gauge transducer 
(SphygmoCor; AtCor Medical, Sydney, Australia) on the radial artery to obtain pressure 
waveforms. Using a generalized validated transfer function
140
, a central aortic pressure 
waveform was reconstructed from the radial artery pressure waveform. Augmentation index 
(AIx) was calculated as the ratio of amplitude of the pressure wave above its systolic shoulder 
(i.e., the difference between the early and late systolic peaks of the arterial waveform) to the total 
pulse pressure. The result was expressed as a percentage and was used as an index of aortic 
pressure wave–reflection intensity. Because AIx is influenced by HR141, AIx values were also 
normalized to a HR of 75 bpm.  
 
3.6.3.5 Aortic Pulse Wave Velocity (PWV) 
PWV was measured following current guidelines
142
. Using the same high-fidelity 
strain-gauge transducer (Sphygmocor, AtCor Medical, Australia) as in the wave reflection 
measurements, pressure waveforms were taken first at the right common carotid artery and then 
at the right femoral artery. Consecutive waveforms were captured for a 10-s epoch. Simultaneous 
ECG gating, as a timing marker, was assessed via a 3-lead CM5 configuration and further used 
to obtain HR
143
. The foot of the pressure wave was identified automatically, removing potential 
observer bias, using an algorithm that detects the initial upstroke via a line tangent to the initial 
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systolic upstroke point of the pressure tracing and an intersecting horizontal line through the 
minimum point
144
.  
Distances from the suprasternal notch to the femoral artery and from the carotid artery to the 
suprasternal notch were measured as straight lines with a tape measure and recorded to the 
nearest mm. The distance from the carotid artery to the suprasternal notch was then subtracted 
from the distance between the suprasternal notch and femoral artery to account for differences in 
the direction of pulse wave propagation.  
Aortic PWV was calculated from the distances between measurement points and the 
measured time delay between 10 proximal and distal waveforms. The peak of the R wave 
recorded from the ECG was used as a timing marker. Values obtained from the carotid to the 
femoral artery (PWV) were taken as an index of “central” arterial stiffness. Integral software 
assessed pulse wave quality (strength of pulse wave signal, pulse height variation, pulse length 
variation, and base line variation) and standard deviation of mean time differences 
(SphygmoCor, AtCor Medical, Sydney, Australia). 
 
3.6.3.6 Echocardiography 
Echocardiography was performed using a multifrequency (1.5-4.25 MHz) transthoracic 
transducer to assess parameters related to cardiac function and systemic vascular resistance. Left 
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ventricular stroke volume was assessed with the Simpson‘s biplane technique. Cardiac output 
was calculated by multiplying the stroke volume by the heart rate. Systemic vascular resistance 
was calculated by dividing the mean arterial pressure by the cardiac output. To minimize the 
effect of variations in fluid volume in hemodialysis patients, studies were performed 18-24 hours 
after a hemodialysis session at all testing timepoints. 
 
3.6.4 Physical Performance Measures 
3.6.4.1 Functional Fitness Testing   
Subjects underwent a battery of tests to assess functional fitness, including: 1) Chair Stand 
Test where subjects were asked to stand up from a seated position as many times as possible 
within 30 seconds; 2) Arm Curl Test in which subjects were asked to complete as many arm curls 
as possible during 30 seconds using either a 5-pound dumbbell for females, an 8-pound dumbbell 
for males; 3) Chair Sit and Reach Test that asked subjects to reach forward with both arms to try 
and touch their extended leg to assess flexibility; 4) Back Scratch Test where subjects tried to 
touch their middle fingers behind their back to assess upper body flexibility; and 5) 8 Foot 
Up-and-Go Test in which subjects were asked to walk around a cone placed 8 feet away from 
their chair and back again during a timed trial.   
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3.6.4.2 Shuttle Walk Test   
Each subject underwent a shuttle walk test to assess physical performance. This is a 
progressive test in which patients walk back and forth continuously on a 10-meter course. The 
walking is paced by beeps which are programmed - the subject should be at the end of the course 
by each beep. They maintain each speed for one minute and then the pace is increased. The 
speeds increase so that in each successive minute the speeds are as follows: 1.12, 1.54, 1.88, 
2.26, 2.64, 3.02, 3.4, 3.78, 4.16, 4.54, 4.92, and 5.3 miles per hour. The patient continues until 
they do not reach the end of the 10-meter course by the beep and the total distance covered is 
calculated. Measures of physical performance such as this shuttle walk test are frequently used to 
assess function in older and diseased people instead of more objective measures of aerobic 
capacity such as VO2max testing. This is due to functional limitations like muscle weakness and 
shortness of breath that prevent these individuals from achieving standard criteria used in 
assessment of these more objective tests
145
. This shuttle walk test is well established as a part of 
the guidelines for assessment of fitness in patients with chronic pulmonary disease
146
, and is 
often preferred to the six-minute walk test because it is paced, and therefore more objective. 
 
3.6.4.3 Muscle Strength Testing   
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A Biodex System 3 Pro dynamometer (Biodex Corp., Shirley, NY) was used to assess 
hamstring and quadriceps strength. The reliability and reproducibility of this device is well 
established.
147
 The subject sat upright on the Biodex chair with the axis of the dynamometer 
corresponding to the knee joint axis. Once the patient was positioned, the shoulder, waist, thigh, 
and lower leg proximal to the ankle were secured with straps. To avoid substitution and 
compensation of other muscle groups, hip belts and a chest restraint were used to prevent hip 
flexion and extension. Isolated isokinetic muscle torque of the knee joint in flexion (hamstring 
muscles) and extension (quadriceps muscles) were evaluated at a speed of 60 degrees per 
second.
147
 There were 2 sets of 6 repetitions, and resting interval of 3 minutes between sets. For 
all tests, participants were verbally encouraged to perform as vigorously as possible. Total 
strength was defined as the sum of peak torque of knee extension and flexion. 
 
3.7 Final Testing   
Six months following the start of the intervention period, all subjects repeated the same 
testing procedures performed at baseline. This included anthropometric measures, vascular 
ultrasound measurements, physical function assessment, and blood draws. All testing was 
conducted by study personnel blinded to the subject’s group assignment. Several factors, 
including blood pressure, heart rate, circulating hormones, and vascular smooth muscle reactivity, 
41 
 
have been implicated in the circadian pattern of cardiovascular events
148
. Thus, each testing and 
measurement session described above occurred approximately at the same time of day within a 
2-hour window as the baseline testing to ensure conformity between baseline and final testing 
measures. 
  
3.8 Data Management, Statistical Analysis and Power Estimates 
3.8.1 Data Management   
Data management and quality control was managed using a Microsoft Excel spreadsheet. 
All data that were not downloaded directly, such as data from serum assays, were entered and 
double checked for accuracy using duplicate entry forms and compare features programmed in 
Microsoft Excel. Confidentiality of data was maintained by using only subject identification 
numbers for data entry. The master document linking participant names and identification 
numbers and group assignment were maintained in a separate password-protected file on a 
secure network accessible only by the mentor (Dr. Wilund); therefore, access to the data was 
restricted. 
 
3.8.2 Statistical Analysis 
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All statistical analysis was performed using SPSS software version 19.0 (IBM Corporation, 
Armonk, NY) and significance was based on a two-tailed alpha value of 0.05. Each participant 
was randomly assigned to one of the two groups (CON, POM) with equal probability. 
Compliance was defined as ingestion of at least 75% of the prescribed POM or placebo 
supplements. The data were screened for the presence of outliers in each of the two treatment 
groups. This was accomplished by using box plots and frequency distributions.  
The general analytic framework for the statistical analysis was a Group*Time mixed model 
ANOVA. The model included the subject as a random effect, and the fixed effects include Group 
as the main effect, and Group*Time as a 2-way interaction. Group (CON or POM) was used as a 
between-subjects factor, and Time (baseline and 6 months) as a within-subjects factor. A 
Chi-square test was used to analyze differences in gender, diabetic and smoking status between 
groups. Correlation analysis was also performed to assess the relationship between selected 
variables of interest. 
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Figure Legends 
Figure 2 Study timeline. Subjects were recruited on a rolling basis and randomly assigned to 
one of the two groups (CON or POM). Patients completed all testing measures at baseline and 6 
months after starting the supplementation period.    
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Figure 2 Study timeline.   
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CHAPTER 4 
RESULTS 
 
4.1 Characteristics of Study Subjects 
Thirty-three of the 75 patients that were recruited agreed to participate in the study. These 
patients were randomly assigned to 2 groups to receive either pomegranate extracts (POM) or 
placebo (CON). Among the 33 enrolled subjects, 6 (POM: N=3; CON: N=3) dropped out of the 
study, including 2 that moved to other cities, 1 that received a kidney transplant, 1 that refused to 
complete the 6-month testing, and 2 that were unable to finish the study due to personal issues. 
The dropout rate was 19% for the POM group, compared to 18% for the CON group (Figure 3). 
Adverse events such as stomach upset or other GI-related effects were not observed among 
subjects. Twenty-seven subjects finished the study, and their 6-month compliance to the study 
intervention (% of pills consumed) was 95.9±1.0% and 98.2±0.6% in POM and CON, 
respectively (p = 0.07).  
As shown in Table 1, general patient characteristics in the POM and CON groups were 
similar at baseline. There were no significant differences between groups in gender, diabetes or 
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smoking status. However, baseline systolic and diastolic blood pressures were both significantly 
higher in POM, compared to CON.  
 
4.2 Cardiovascular Outcomes 
There was a significant interaction between group and time for systolic and diastolic blood 
pressure, as they decreased by 12.8±0.1% (F1, 25 = 6.00; p < 0.05) and 11.2±0.1% (F1, 25 = 7.80; p 
< 0.05), respectively, in POM, but did not change in CON (Figure 4). However, the changes in 
blood pressure in the POM group were no longer significant after controlling for subject’s 
baseline blood pressure. There were no interactive or main effects of group and time on heart 
rate, CIMT, PWV, -stiffness, augmentation index, stroke volume, cardiac output, or systemic 
vascular resistance (Table 2). 
 
4.3 Physical Performance Outcomes 
 There were no interactive or main effects of activity group and time on gait speed, shuttle 
walk time, functional fitness tests, or muscle strength (Table 2). 
 
4.4 Markers of Inflammation and Oxidative Stress 
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There were no interactive or main effects of activity group and time on CRP, IL-6 8-OHdG, 
AOPP, ox-LDL, ORAC, arylesterase, or paraoxonase (Table 2). There was a significant 
interaction between group and time for lactonase activity, as it increased by 5.4±1.7 kU/L, or 
26.6%, (F1, 25 = 4.58, p < 0.05) in POM, compared to no change in CON . 
The change in total cholesterol was positively correlated with the change of ox-LDL (r 
=0.49, p = 0.01) and the change in AOPP (r = 0.42, p = 0.03). The change in ox-LDL was 
inversely correlated with the change in ORAC (r = -.38, p = 0.04), and positively correlated with 
the change in 8-OHdG (r = 0.50, p = 0.01). No other significant correlations between major 
outcome variables were found. 
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Figure Legends 
Figure 3 Study flowchart. Thirty-three patients were recruited and randomly assigned to either 
pomegranate extracts (POM) or placebo (CON). Six patients (POM: N=3; CON: N=3) dropped 
out of the study. The dropout rate was 19% for the POM group, compared to 18% for the CON 
group. Twenty-seven subjects finished the 6-month intervention. 
 
Figure 4 Blood pressure changes from baseline to 6 months. Patients in both the POM and 
CON groups had blood pressure measured at baseline and 6-month testing. SBP and DBP both 
decreased from baseline to final testing in the POM group (p< 0.05), but did not change in the 
CON group. 0M and 6M indicate baseline and 6-month testing time points, respectively. Values 
are given as mean±S.E. Mean; Data was analyzed by 2-way ANOVA. * indicates p<0.05 for 
group x time interaction effect. # indicates p < 0.05 for baseline levels between groups.  
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Figure 4 Blood pressure changes from baseline to 6 months. 
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Table 1 Patient characteristics at baseline.  
Characteristic POM (N=13) CON (N=14) p value 
Age (years) 52.6±3.3 55.9±2.6 .45 
Gender (Male %) 61.5 64.3 .88 
Ethnicity   .51 
  Caucasian (%) 15.4 7.1  
  African American (%) 84.6 85.8  
  Hispanic or Latino (%) 0 7.1  
Diabetes mellitus (Yes %) 53.8 35.7 .34 
Smoking status (Yes %) 30.8 28.6 .91 
Vintage (months) 75.5±14.1 59.8±10.6 .39 
Etiology of CKD   .51 
  Uncertain (N) 4 2  
  Hypertension (N) 6 10  
  Diabetes (N) 2 2  
  Polycycstic Kidney Disease (N) 1 0  
  Chronic Glomerulonephritis (N) 0 0  
  Chronic Pyelonephritis (N) 0 0  
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Table 2 Outcome variables at baseline and final testing.  
Outcomes POM (N=13) CON (N=14) 
 N 0M 6M N 0M 6M 
Weight (kg) 12 96.6±8.0 89.9±6.4 14 87.7±8.0 88.7±7.6 
Height (cm) 11 167.3±2.9 167.0±2.7 14 167.3±2.1 167.4±2.0 
BMI (kg/m
2
) 11 32.3±2.1 31.7±2.1 14 31.1±2.5 31.5±2.4 
Body fat percentage (%) 11 29.1±3.1 28.9±3.1 13 29.6±2.6 29.5±2.5 
Waist circumference (cm) 13 110.0±5.7 107.3±5.1 14 105.7±6.5 106.9±6.5 
Albumin (g/dl) 13 4.0±0.1 4.0±0.1 14 3.9±0.1 4.0±0.1 
Kt/V 6 1.6±0.1 1.6±0.1 11 1.6±0.1 1.6±0.1 
       
Cardiovascular outcomes       
SBP (mmHg) 13 156.8±10.1# 132.7±11.5* 14 127.1±6.1 132.6±8.2 
DBP (mmHg) 13 85.8±4.0# 74.8±4.4* 14 69.2±3.3 73.5±3.7 
Mean arterial pressure (mmHg) 13 109.3±5.6# 96.9±5.7* 14 88.4±3.8 93.4±4.6 
Heart rate (beats/min) 13 72.9±3.3 68.0±8.2 14 69.3±3.6 68.6±2.9 
PWV (m/s) 13 10.2±1.2 11.5±1.6 11 8.6±0.6 10.4±1.4 
CIMT (mm) 12 0.54±0.10 0.76±0.04 14 0.70±0.10 0.74±0.06 
β-stiffness 12 12.0±2.1 11.3±1.7 12 10.4±1.7 11.6±1.6 
Augmentation index (%) 10 32.0±2.1 34.1±5.6 14 23.6±2.2 21.1±3.6 
Stroke volume (ml/beat) 10 52.5±4.4 57.5±6.0 12 53.9±4.0 51.0±6.2 
Cardiac output (L/min) 10 3.9±0.4 4.3±0.4 12 3.4±0.2 3.4±0.4 
Systemic vascular resistance 
(mmHg/L/min) 
10 30.1±3.6 24.7±2.4 12 27.5±2.2 33.6±5.8 
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Table 2 (cont.) 
Outcomes POM (N=13) CON (N=14) 
Physical performance outcomes N 0M 6M N 0M 6M 
Walk speed (sec) 12 12.4±1.1 13.4±1.2 14 12.0±1.2 11.7±0.9 
Shuttle walk time (sec) 12 234.8±44.5 207.8±40.8 14 268.3±33.3 262.7±31.1 
Peak torque RKF (ft*lb) 12 39.2±4.7 43.5±7.7 14 34.8±3.7 36.0±5.4 
Peak torque RKE (ft*lb) 12 67.6±8.7 75.6±11.4 14 64.5±6.6 76.3±10.6 
Peak torque LKF (ft*lb) 12 37.3±5.7 40.9±5.8 14 31.4±4.1 37.0±5.3 
Peak torque LKE (ft*lb) 12 69.7±9.8 70.0±9.0 14 65.8±7.9 79.6±12.1 
Chair stand (repetitions) 12 11.3±2.4 9.5±1.9 13 10.5±1.2 10.2±1.1 
Arm curl (repetitions) 12 14.4±2.3 13.7±2.6 14 14.6±1.3 14.4±1.1 
Sit and reach (inches) 12 -4.1±1.0 -3.3±0.9 13 -2.9±1.4 -2.5±1.3 
Back scratch (inches) 13 -5.8±1.7 -4.6±1.3 14 -4.9±1.3 -5.7±1.2 
8-foot up and go (seconds) 12 9.4±1.6 10.3±2.2 14 8.3±1.4 7.6±0.8 
 
54 
 
Table 2 (cont.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0M and 6M indicate baseline and 6-month testing time point, respectively. Kt/V, K represents dialyzer clearance of urea, t represents dialysis time, and V 
represents volume of distribution of urea. SBP, systolic blood pressure; DBP, diastolic blood pressure; PWV, pulse wave velocity; CIMT, carotid intima-media 
thickness; RKF, right knee flexion; RKE, right knee extension; LKF, left knee flexion; LKE, left knee extension; ORAC, oxygen radical absorbance capacity; 
AOPP, advanced oxidation products of proteins; 8-OHdG, 8-hydroxy-2’-deoxyguanosine; ox-LDL, oxidized low-density lipoprotein; IL-6, interleukin 6; CRP, 
c-reactive protein; paraoxonase, PON-1 activity towards paraoxon; arylesterase, PON-1 activity towards phenyl acetate; Lactonase, PON-1 and PON-3 activity 
towards dihydrocoumarin. PON-1 activities are expressed as µ moles of hydrolyzed substrate per minute per liter of serum (U/L) or mmol/min/liter (kU/L) as 
indicated. Values are reported as mean±S.E. Mean; Data was analyzed by 2-way ANOVA. * indicates p<0.05 for group x time interaction effect. Baseline data 
was analyzed by Student’s t-test or Pearson Chi-Square test. # indicates p < 0.05 for baseline levels between groups. 
Outcomes POM (N=13) CON (N=14) 
Plasma and serum variables N 0M 6M N 0M 6M 
Total cholesterol (mg/dl) 13 177.7±13.3 186.0±18.5 14 149.6±11.5 157.3±17.1 
HDL (mg/dl) 12 48.8±4.9 47.6±4.6 14 49.7±4.5 47.1±4.3 
LDL (mg/dl) 12 103.3±13.2 117.5±18.2 14 83.0±12.3 92.0±16.8 
Triglyceride (mg/dl) 13 128.2±32.9 104.3±22.2 14 84.8±30.4 91.1±20.5 
ORAC (uM) 13 17933.2±2907.0 16586.9±1827.7 14 18100.5±1530.6 17415.0±1391.3 
AOPP (uM) 13 163.6±19.9 144.4±10.8 14 165.1±10.5 141.3±13.2 
8-OHdG (ng/ml) 13 34.3±3.2 33.1±3.0 14 31.4±3.9 31.5±2.9 
Ox-LDL (U/L) 13 34.4±5.1 34.1±6.5 14 31.4±3.9 27.8±4.4 
Arylesterase (kU/L) 13 36.1±2.4 37.0±3.5 14 36.0±3.0 41.8±3.2 
Lactonase (kU/L) 13 20.3±2.1 25.7±2.4* 14 25.1±2.1 25.5±2.5 
Paraoxonase (U/L) 13 707.3±117.0 746.5±127.7 14 741.2±121.3 796.1±130.0 
IL-6 (pg/ml) 13 7.5±2.1 7.6±1.7 14 7.6±1.9 7.4±1.4 
CRP (mg/L) 13 11.6±4.4 14.4±4.8 14 5.7±2.3 4.6±1.5 
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CHAPTER 5 
DISCUSSION 
 
The present study is the first study to investigate the effect of pomegranate extract on 
cardiovascular health and physical function in patients with chronic kidney failure. Our primary 
finding was that both systolic and diastolic blood pressure was significantly reduced in patients 
after 6 months of pomegranate supplementation. However, because baseline blood pressures 
were higher in the POM group, it cannot be ruled out that these changes may have been due to a 
regression to the mean. Pomegranate supplementation had no effect on any other metrics of 
cardiovascular risk or physical function in our patients. Taken together, this data suggests that 
pomegranate extract supplementation may provide limited benefits in terms of reducing the 
development or progression of co-morbidities in patients with chronic renal failure.  
Oxidative stress is believed to affect blood pressure through a variety of mechanisms
149, 150
. 
Increased oxidative stress contributes to vascular dysfunction by reducing the bioavailability of 
nitric oxide (NO), which is a major vasodilator (reviewed in
151
). Oxidation of L-arginine and 
tetrahydrobiopterin (BH4), which are two essential cofactors for endothelial NO synthase 
(eNOS), results in the decreased formation of NO. In addition, oxidative stress in vascular smooth 
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muscle cells (VSMCs) can cause cell proliferation or apoptosis, and further contributes to changes 
in blood vessel diameter and blood pressure
152
. Antioxidants have been shown to improve 
vascular dysfunction induced by excessive oxidative stress
151
. Antioxidant supplementation, such 
as vitamin C or E, has shown to protect against endothelial damage by upregulating eNOs and 
scavenging reactive oxygen species
153
. It is well-established that polyphenolic antioxidants, such 
as red wine and pomegranate, can function as ROS scavengers, enhance the production and 
bioavailability of NO, thereby improving vascular resistance and possibly may respond to changes 
in blood pressure
16, 105, 154-157
. Though not statistically significant, there was a trend for a 
reduction in TPR in the POM group (p = 0.11 for group x time interaction), suggesting that 
changes in vascular resistance may have partially contributed to the BP reduction in POM.  In 
addition, several studies have demonstrated reductions in blood pressure following pomegranate 
juice consumption in hypertensive subjects and in patients with carotid artery stenosis
16, 158, 159
, 
so there is precedent for the blood pressure reductions that we found following pomegranate 
extract supplementation in our patients. This also suggests that the blood pressure changes we 
found may not have been solely due to a regression to the mean. Aviram et al. identified a 
potential mechanism for the blood pressure lowering effect of pomegranate, suggesting that it 
directly interacts with serum angiotensin converting enzyme (ACE). They incubated human 
serum with different concentrations of pomegranate juice, and found a pomegranate juice 
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dose-dependent inhibitory effect on serum ACE activity
159
. However, they found no correlation 
between the reduction in ACE activity and BP, suggesting the reduction in ACE activity may not 
be the major factor contributing to pomegranate-induced BP changes.  
Research also suggests that pomegranate provides additional cardiovascular benefits besides 
reducing blood pressure. CIMT has been used as a validated surrogate end-point for 
atherosclerosis and vascular disease risk
19, 160
. Aviram et al. found a 30% reduction in CIMT 
among subjects with severe carotid artery stenosis after 1 year of pomegranate juice 
consumption
16
. Pomegranate juice was also reported to decrease the CIMT progression rates in 
subjects at moderate risk for coronary heart disease
123
, and improved a composite score of CIMT 
in hemodialysis patients
19
. Despite these previous studies showing beneficial effects of 
pomegranate juice on CIMT in clinical populations, the present study did not find CIMT 
improvements with 6 months of pomegranate extract consumption. This discrepancy in the 
CIMT findings might be due to different forms of supplementation (i.e., powder extracts versus 
juice), as well as a shorter period of intervention (i.e., 6 months versus more than 1 year) in the 
present study. Although Aviram et al.
16
 found a reduction in CIMT as soon as 3 months of 
pomegranate juice consumption in subjects with severe carotid stenosis, our dialysis patients had 
relatively thinner CIMT at baseline (0.54mm CIMT in our study versus 1.52mm CIMT in 
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Aviram et al.), which might be another potential reason that we did not see changes in CIMT 
after 6 months of pomegranate extract supplementation.  
Our findings are contrary to prior studies suggesting antioxidant supplementation, such as 
vitamin C and/or E, would reduce vascular disease risk by decreasing arterial stiffness in subjects 
with diabetes or hypertension
161, 162
. However, Dohadwala et al. showed that PWV did not 
change after a 4-week intervention with cranberry juice, which contains abundant polyphenolic 
compounds, in patients with coronary artery disease
163
. Although there is little evidence of 
reducing arterial stiffness by pomegranate supplements in clinical populations, consumption of 
pomegranate juice for 4 weeks had no effect on PWV in healthy subjects
164
. Longer clinical trials 
are needed to investigate the effects of polyphenolic compounds on arterial stiffness to confirm 
these findings. 
Although studies have shown that low plasma antioxidant levels (e.g., tocopherol, 
carotenoids) are associated with poor skeletal muscle strength and impaired physical 
performance in older adults
112, 165, 166
, to our knowledge, only a few studies have directly 
investigated the effects of antioxidant supplementation on these metrics. A recent study by Hauer 
et al. found that N-acetylcysteine (NAC) combined with resistance exercise training improved 
muscle strength in the elderly after 13 weeks
13
. However, these data must be interpreted with 
caution because plasma antioxidant levels were not reported to confirm the relationship between 
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changes of antioxidant level and improved muscle performance. In addition, the improvements in 
physical performance and muscular strength were not only observed in the group with NAC 
supplementation combined with resistance exercise, but also in the group with placebo combined 
with resistance training. These results suggested the functional improvements may be due to 
resistance training response or learning effects, instead of antioxidant benefits solely. 
Pomegranate juice has been used as an antioxidant supplement to improve recovery of 
elbow flexor strength, as well as to attenuate soreness, after a single damaging bout of eccentric 
exercise in healthy subjects
14, 15
. However, our data did not show that pomegranate 
supplementation chronically improves physical function or muscle strength in dialysis patients. 
This inconsistency may be due to the different populations and functional measures that were 
assessed, or the fact that we assessed chronic changes in function, as opposed to recovery from a 
single bout of exercise.  
Paraoxonase-1 (PON1) is the most potent HDL-associated antioxidant enzyme, and uremic 
toxins may play a mechanistic role in PON1 inactivation
167
. Past studies have reported widely 
variable PON-1 activity in hemodialysis patients
137, 168-170
, which may be explained in part by 
differences in subject’s BMI, nutritional status, CRP levels, vintages of hemodialysis, or 
differences in assay methods used in each study
170
. However, we did not find any relationship 
between PON-1 activity and patient’s BMI, dialysis vintages, albumin or CRP levels. 
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Pomegranate juice has shown to increase the paraoxonase, arylesterase and lactonase 
activities of PON-1
123, 131
. PON-1 hydrolyzes organophosphate compounds (e.g., paraoxon) and 
aromatic carboxylic acid esters (e.g., phenyl acetate), and possesses peroxidase-like activity that 
can contribute to its protective effect against lipoprotein oxidation
135, 171
. PON-1 also provides its 
anti-atherogenic properties through a homocysteine-thiolactonase activity
134, 172
. Among 
arylesterase, paraoxonase and lactonase, we only found an increase in lactonase activity in the 
POM group. Although these results differ from some published studies showing that PON-1 
activity toward other substrates improved after pomegranate juice consumption
124, 136
, they are 
consistent with the recently accumulating evidence suggesting that the lactonase activity is the 
most significant explanation for PON-1’s atheroprotective properties137, 173-175.  
PON-1 activity largely depends on its association with HDL. However, we did not find an 
association between the change in HDL cholesterol concentration and change of PON-1 
activities in the present study, suggesting that the change in lactonase activity is not related 
solely to changes in HDL concentration in hemodialysis patients. This finding is in agreement 
with those by Gugliucci et al., which showed no correlation between lactonase activity and HDL 
levels in CKD patients, and might be due to the inhibition of enzyme catalysis and synthesis by 
uremic toxins
137
.  
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Punicalagin, an ellagitannin found in pomegranate, accounts for 70-89% of the antioxidant 
activity of pomegranate juice
116, 176
, and studies have shown that pomegranate juice and extracts 
have similar bioavailabilities. Our 1,000-mg pomegranate extract contains approximately 755 mg 
of gallic acid equivalents
177
. This is similar to a typical 8-ounce serving of pomegranate juice, 
which contains 857 mg of gallic acid equivalents. As a result, we chose to use the pomegranate 
extract in this study, as opposed to the juice, due to the high content of potassium in pomegranate 
juice, and restrictions on the intake of these minerals in dialysis patients. 
Despite very similar antioxidant contents in juice and extracts, prior work on ellagitannin 
absorption yielded variable results. Seeram et al. showed that ellagic acid concentration in 
plasma reached its peak concentration 2-3 hours after consuming pomegranate extract, compared 
to a peak plasma ellagic acid concentration at 1 hour following consumption of pomegranate 
juice
177
. By contrast, Cerda et al. found that neither punicalagin nor ellagic acid were detected in 
plasma after consuming 1 liter of pomegranate juice per day for 5 days
178
. The different 
absorption rates between pomegranate juice and extracts may contribute to the inconsistent 
findings from the current study, compared to the previous work published by Shema-Didi et al.
19
, 
who reported that pomegranate juice provided anti-inflammatory and cardioprotective benefits in 
hemodialysis patients.  
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A potential explanation for why we observed no POM-induced change in circulating 
markers of inflammation or oxidative stress in the present study may be due to the abnormal 
distribution of microflora in hemodialysis patients. Cerda et al. suggested that the poor 
absorption of ellagic acid was explained by its poor solubility at physiological pH in the 
intestine, and its poor ability to bind to intestinal epithelium
179, 180
. Cerda also suggested that the 
cardiovascular protective effects of pomegranate might be due to metabolites produced from 
pomegranate digestion by intestinal microflora, such as urolithins, rather than to the polyphenolic 
concentration present in the pomegranate products
178
. Excessive uremic toxins, CKD-related 
comorbidities, medications, and irregular dietary patterns, which are all conditions commonly 
seen in hemodialysis patients, may cause an abnormal distribution of microflora in the 
gastrointestinal tract and change of gastrointestinal permeability
181
. Indeed, we found no 
difference in ORAC, a measure of serum total antioxidant capacity, between groups at 1.5 and 3 
hours after pomegranate extract or placebo ingestion (data not shown). The abnormal distribution 
of microflora in CKD patients might result in a reduction in antioxidant absorption, thereby 
attenuating the potential antioxidant, and anti-inflammatory effects of pomegranate in 
hemodialysis patients. Further research is needed to investigate the concentration of ellagic acid 
in plasma after ingesting pomegranate products to determine the absorption rate of antioxidant in 
patients undergoing hemodialysis treatment.  
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Limitations 
There are several limitations to our study. Primarily, the sample size was relatively limited, 
thereby reducing the statistical power for the analysis. This also inhibited us from controlling for 
subjects’ medication status and intercurrent illness, both of which may have affected our primary 
outcomes. In addition, we did not measure plasma levels of ellagic acid to confirm whether the 
subjects were actually taking pills during the intervention.  
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CHAPTER 6 
CONCLUSIONS 
 
Chronic kidney disease patients undergoing hemodialysis therapy suffer from a variety of 
co-morbidities that may be mechanistically linked, such as reduced exercise capacity, increased 
cardiovascular risk, and elevated inflammation and oxidative stress. These co-morbidities not 
only contribute to the low quality of life, but also increase the mortality rate in this population. 
Because current pharmacological therapies have failed to significantly reduce uremic-related 
co-morbidities in hemodialysis patients, the present study was designed to determine the effects 
of pomegranate supplementation, a rich source of polyphenol antioxidants, on CVD risk, 
physical performance, inflammation and oxidative stress. The present study suggests modest 
benefits of 6-months pomegranate extract supplementation in patients undergoing hemodialysis, 
including (1) possible reductions in blood pressure, and (2) an increase in serum antioxidant 
activity. However, pomegranate extract supplementation had no effect on other markers of 
cardiovascular risk, or muscle strength and function. Though past studies demonstrated relatively 
robust cardioprotective effects of pomegranate juice consumption in various clinical populations, 
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including hemodialysis patients
16, 19, 123, 125, 158, 159
, our data indicates that the benefits of 
pomegranate extract supplementation may be limited in hemodialysis patients. 
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